N4P
NEUTRALN4 Pharma Provides AGM Update on Nuvec® Platform Progress
The biotech company updates on the development of its Nuvec® gene delivery system, highlighting upcoming work to strengthen the commercial data package.
N4 Pharma
0.3750GBX
0.00%
Market Cap
3.12M
Volume
1.25k
0% of avg
P/E Ratio
EPS (TTM)
Beta
0.71
Day Range
0.0000p - 0.0000p
52 Week Range
0.0000p0.3750p0.8000p
0.3750p
Upcoming Events
N4P
NEUTRALN4 Pharma to Host Investor Insight Event
The biotech company is hosting an investor event to provide updates on its Nuvec® gene delivery system and pipeline.
N4P
BADN4 Pharma Reports Progress in Pre-Clinical Studies Amid Continued Losses
The pre-clinical biotech firm reported progress in its studies but continues to face financial challenges with ongoing losses and a decreasing cash position, highlighting the risks inherent in early-stage pharmaceutical development.
N4P
NEUTRALN4 Pharma Establishes New Senior Leadership Team
The biotech company has formed a new senior leadership team to support its strategic and scientific objectives, including experts in drug development, commercial strategy, and manufacturing.
N4P
NEUTRALN4 Pharma Announces Director Dealings
The healthcare company has announced a change in major shareholdings.
N4P
NEUTRALN4 Pharma Plc Announces Director Dealings
The healthcare company has announced a transfer of shares between two of its subsidiaries.
N4P
NEUTRALN4 Pharma Announces Change of Registered Address
The biotech company has changed its registered address to a new location in London.
N4P
NEUTRALN4 Pharma Reports Positive In Vivo Study Results for Nuvec Delivery Platform
The biotech company reports positive results from an in vivo study of its Nuvec delivery system for an inflammatory bowel disease treatment, showcasing the platform's potential.
N4P
NEUTRALN4 Pharma Plc Announces Holding(s) in Company
The healthcare company has announced a change in major shareholding, with Tracarta Limited now holding 18.02% of the voting rights.
N4P
NEUTRALN4 Pharma Plc Announces Director Dealings
The healthcare company has announced changes to its director shareholdings.